SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Fosaprepitant for Injection and ...

Geospatial Genomics: Operationalizing Multilevel Conceptual Frameworks of Cancer Health Outcomes to Account for Gene-Person-Place Relationships At the time of the primary PFS analysis, interim ...

Capivasertib, a potential first-in-class AKT inhibitor, combined with FASLODEX could become a new option for patients in this setting regardless of biomarker status WILMINGTON, Del.--(BUSINESS WIRE)-- ...

Avenacy, a specialty pharmaceutical company focused on supplying injectable medications, has launched Fosaprepitant for Injection and Fulvestrant Injection. “Avenacy has had a strong start to 2024, ...

What is capivasertib and fulvestrant? Capivasertib and fulvestrant is a treatment for breast cancer that has spread to the surrounding tissue (locally advanced). Or if it has spread to other parts of ...

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining ...

VeraMorph Awarded an SBIR Fast Track Grant by NCI Towards Commercialization of the First Effective Oral Fulvestrant Therapy for ER+ Metastatic Breast Cancer Veramorph LLC (VeraMorph), a science-driven ...

A total of 62 patients were initially screened across five study centers for eligibility in this study. Of these, 15 patients were excluded due to various reasons: 10 failed the screening, 3 declined ...

Comparison of the Efficacy of Local Therapies for Localized Prostate Cancer in the Prostate-Specific Antigen Era: A Large Single-Institution Experience With Radical Prostatectomy and External-Beam ...